RIGVIR represents group of companies that produce and develop oncolytic virotherapy medicines containing ECHO7 - Live oncolytic and oncotropic virus with immunomodulation activity for cancer treatment. Leading agent - RIGVIR - is approved for treatment of Melanoma skin cancer.
We are looking for partner who could facilitate development of our treatment agents both as an collaborative R&D partner or investor in order to successfully commercialise the drug globally.